Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02934269 · ClinicalTrials.gov registry record · Phase 1
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-90006 in Healthy Subjects
A Phase 1 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT02934269 is a Phase 1 study that has completed, run by Celgene. The registered enrollment target is 40 participants.
The verdict
NCT02934269, a Phase 1 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of CC-90006 following administration of single subcutaneous doses in healthy subjects.
Interventions
- DRUG Placebo
- DRUG CC-90006
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2016-11-21 |
| Est. Completion | 2017-08-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02934269
The ClinicalTrials.gov registry entry for NCT02934269 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02934269 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02934269 about?
NCT02934269 is a clinical study titled "A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-90006 in Healthy Subjects". This is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of CC-90006 following administration of single subcutaneous doses in healthy subjects.
What is the current status of trial NCT02934269?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2016-11-21. Estimated completion is 2017-08-15.
What interventions are being tested in trial NCT02934269?
The interventions under investigation include: Placebo (DRUG), CC-90006 (DRUG).
Who is sponsoring clinical trial NCT02934269?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.